Meropenem Kalceks

Meropenem, the active ingredient in Meropenem Kalceks, is a carbapenem antibiotic presented as a intravenous formulation for intravenous use. It treats severe bacterial infections in hospitalized patients, including those caused by multidrug‑resistant organisms.

GNH USA supplies Meropenem Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious infections caused by Gram‑negative, Gram‑positive and anaerobic bacteria.

- Complicated intra‑abdominal infection: achieves clinical cure by eradicating mixed aerobic and anaerobic pathogens. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: provides rapid bacterial clearance. - Complicated urinary tract infection: eliminates resistant Enterobacteriaceae. - Sepsis and septic shock: offers bactericidal activity against a wide range of pathogens. - Meningitis caused by susceptible organisms: penetrates the cerebrospinal fluid to treat infection.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Infusion site phlebitis: pain or redness at IV site. - Elevated liver enzymes: transient increase in transaminases. - Headache: mild discomfort.

Serious or Rare Side Effects: - Seizure: risk increases with high doses or renal impairment. - Clostridioides difficile‑associated colitis: severe diarrhea and colitis. - Anaphylaxis: acute hypersensitivity reaction. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible patients. - Hemolytic anemia: rare immune‑mediated destruction of red cells.

Meropenem should be used with careful clinical assessment and monitoring.

- Renal function assessment: adjust dosing in patients with impaired kidney function. - Allergy assessment: avoid in individuals with known carbapenem hypersensitivity. - Seizure risk: monitor patients with central nervous system disorders or receiving high doses. - Valproic acid co‑administration: avoid as meropenem reduces serum valproate levels. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several concomitant medications.

Major Interactions (Avoid): - Valproic acid: co‑administration can markedly decrease valproate concentrations, increasing seizure risk. - High‑dose aminoglycosides: combined nephrotoxic potential may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance renal clearance, requiring dose review. - Warfarin: possible alteration of INR, necessitating coagulation monitoring. - Other broad‑spectrum antibiotics: may increase risk of C. difficile infection. - Antacids containing magnesium or aluminum: can reduce meropenem absorption if administered orally (rare for IV).